Niemann-Pick disease type C (NPC) is a genetic disorder in which patient cells exhibit lysosomal accumulation of cholesterol and sphingolipids (SLs) caused by defects in either NPC1 or NPC2 proteins. We previously demonstrated that NPC1 human skin fibroblasts overexpressing endosomal Rab proteins (Rab7 or Rab9) showed a correction in the storage disease phenotype. In the current study, we used protein transduction to further investigate Rab9-mediated reduction of stored lipids in NPC cells. Recombinant human Rab9 fused with the herpes simplex virus VP22 protein fragment was overexpressed, purified, and added to culture medium to induce protein transduction. When VP22-Rab9 was transduced into NPC1 fibroblasts, nearly all cells showed significant reduction in cellular free cholesterol levels, with no cytotoxicity up to 5 μM. A fraction of the VP22-Rab9 that was transduced into the cells was shown to bind to rab GDP dissociation inhibitor, suggesting that this pool of VP22-Rab9 had become prenylated. The reduction in cellular free cholesterol was associated with correction of abnormal intracellular trafficking of BODIPY-lactosylceramide and an increase of sterols in the culture media. The clearance of lysosomal free cholesterol was also associated with a decrease in LDL-receptor levels. In addition, we demonstrated reduction of intracellular cholesterol by VP22-Rab9 transduction in NPC2 fibroblasts and in cultured mouse NPC1 neurons. These observations provide important new information about the correction of membrane traffic in NPC cells by Rab9 overexpression and may lead to new therapeutic approaches for treatment of this disease.
protein localized in late endosomes. The remainder of patients has mutations in the NPC2 gene, which encodes a soluble lysosomal protein that binds cholesterol. The hallmark of NPC cellular pathology is a defect in intracellular vesicular lipid trafficking associated with accumulation of unesterified free cholesterol, glycosphingolipids, and other lipid species in late endosomes/lysosomes of various tissues. Cultured NPC fibroblasts also show massive accumulation of free cholesterol, which can be seen as intense, punctate staining in cells using filipin, which fluoresces upon binding to free cholesterol (2) . Currently, no successful treatments of NPC are available (1) .
We have been studying the mechanism of endocytic trafficking using a fluorescent glycosphingolipid analog, N- [5-(5,7- dimethyl boron dipyrromethene difluoride)-1-pentanoyl]-1′,1-lactosyl-D-erythro-sphingosine (BODIPY-LacCer) (3) , and found that many SLSDs show a common alteration in intracellular transport of this lipid analog despite differences in the primary defect (4) (5) (6) . In normal human skin fibroblasts (HSFs), BODIPY-LacCer is transported to the Golgi apparatus via Rab7-and Rab9-dependent mechanisms (7) . In most SLSDs including NPC1 and NPC2 cells, however, this lipid accumulates in the endosomes and lysosomes. This lipid trafficking defect has been shown to be associated with cellular accumulation of free cholesterol in SLSD cells (8, 9) . Surprisingly, we found that the overexpression of wild-type Rab7 or Rab9 in NPC1 mut cells resulted in restoration of normal BODIPY-LacCer targeting to the Golgi, as well as a reduction in filipin staining of free cholesterol and an increase in Nile Red staining of neutral lipids (7) . Correction of lipid trafficking in NPC1 cells by rab9 overexpression was also observed in a study by Walter et al. (10) .
To learn more about the role of Rab proteins in modulating lipid traffic and lipid accumulation in NPC cells, and to develop the therapeutic potential of this system, an alternative method to conventional DNA transfection is required to introduce rab proteins into living cells. One possible technique is protein transduction, in which a protein of interest is fused to a membranepermeable peptide or protein motif called a protein transduction domain (PTD) (11) (12) (13) . PTDs include the human immunodeficiency virus transcription factor TAT, the Drosophila melanogaster homeobox protein Antennapedia, and the herpes simplex virus type 1 tegument protein VP22. In the present study, we report construction of VP22-Rab9 protein and correction of NPC phenotypes in cultured cells using this protein. We then investigate the mechanisms by which Rab9 overexpression reduces intracellular cholesterol. Finally, we show a reduction in lipid storage in cultured mouse NPC1 mut neurons by VP22-Rab9. These observations provide important new information about the correction of membrane traffic in NPC and may lead to new therapeutic approaches for treatment of this disease.
MATERIALS AND METHODS
Eagle's minimum essential medium (EMEM; Biofluids; Rockville, MD), McCoy's 5A (SigmaAldrich; St. Louis, MO), fetal bovine serum (FBS; Life Technologies; Rockville, MD), fetal bovine lipoprotein deficient serum (LPDS; Intracel; Frederick, MD), and defatted bovine serum albumin (DF-BSA; Intergen; Purchase, NY) were from the indicated sources. Oligonucleotide primers for PCR, DNA sequencing, and site-directed mutagenesis primers were synthesized at the Mayo Clinic Molecular Biology Core Facility. Voyager NES protein production kits containing plasmid vector pCRT7/VP22/NES-1 and E. coli strain BL21(DE3)pLysS were from Invitrogen (Carlsbad, CA), and QuikChange Site-Directed Mutagenesis Kit and E. coli strain XL1-Blue were from Stratagene (La Jolla, CA). His•Bind Columns and Benzonase Nuclease were from Novagen (Madison, WI). EDTA-free Complete protease inhibitor cocktail, anti-myc monoclonal antibody, and restriction enzymes were from Roche Applied Science (Indianapolis, IN). SlowFade antifade kit and Nile red were from Molecular Probes (Eugene, OR). Anti-Rab9 monoclonal antibodies were from S. Pfeffer (Stanford University) and Affinity BioReagents (Golden, CO). Filipin was from Polysciences (Warrington, PA). Cholesterol and cholesterol oleate were from Sigma.
Fibroblasts and culture conditions
Normal HSFs (GM5659) and NPC1 mut human skin fibroblasts (NPC1 ), and NPC2 null (splicing defect mutation in the intron after exon 1) human fibroblasts were from the NPC Cell Repository of the Division of Laboratory Genetics at the Mayo Clinic. Unless otherwise noted, cells were cultured in EMEM containing 10% FBS as described previously (3) . Cells were cultured on glass coverslips in 35 mm culture dishes for microscopy experiments and in 100 mm dishes for biochemical studies.
VP22-Rab9 fusion proteins
The cDNA sequence of human Rab9 in pcDNA3.1 (3) was amplified by PCR and ligated in frame into the PinAI site of plasmid vector pCRT7/VP22/NES-1 to express a fusion Rab protein with VP22/NES/myc/polyHis tag sequence at the N terminus. The protein expressed from this plasmid was designated VP22-Rab9 (Fig. 1A) . The mutant forms of VP22-Rab9, VP22-Rab9S21N (dominant-negative), and VP22-Rab9Q66L (constitutively-active) (14) were generated with the QuikChange site-directed mutagenesis kit. Each plasmid DNA was amplified in E. coli XL1-Blue, and the sequence and direction of the insert were confirmed by DNA sequencing.
VP22-Rab proteins were expressed in BL21(DE3)pLysS cells and purified using His•Bind columns following the manufacturer's protocol. In some cases, protein eluted from His•Bind columns was further purified on a Superose 12 16/50 gel filtration column (Amersham Biosciences, Piscataway, NJ) as described previously (15) . Fractions containing purified VP22-Rab9 were concentrated using Centriprep YM-30 filters (Millipore, Bedford, MA). Protein concentration was determined with the Bio-Rad protein assay (Hercules, CA) using bovine serum albumin as a standard. For cell culture experiments, VP22-Rab9 samples were exchanged into culture medium using PD-10 desalting columns (Amersham Biosciences).
Protein transduction
Fibroblasts were incubated with 0.2-5.0 μM VP22-Rab9 protein for various times at 37°C in EMEM containing 1-10% FBS, or in McCoy's 5A medium containing 5% LPDS (see figure  legends) . Incubation conditions were optimized by assessing the reduction of filipin staining (see below). The cytotoxicity of VP22-Rab9 treatment was evaluated using Trypan blue. Treatment of cells with VP22-Rab9 resulted in a variable amount of extracellular, aggregated protein, as observed by phase microscopy; however, these aggregates had no apparent effect on cell viability.
To detect cell-association of unlabeled VP22-Rab9, cells cultured in 60-mm dishes were treated with VP22-Rab9 for 48 h, scraped, and homogenized in 50 mM HEPES, pH 7.2, 100 mM KCl, 10% glycerol, in the presence of protease inhibitors. The protein samples were separated by SDS-PAGE, transferred to nitrocellulose membranes, and detected by immunoblotting using an anti-Rab9 monoclonal antibody.
To determine if VP22-Rab9 became prenylated after transduction, the interaction between cellassociated VP22-Rab9 and Rab GDI dissociation inhibitor (Rab GDI), which binds only prenylated Rabs (16, 17) , was investigated. NPC cells were transduced with VP22-Rab9 as above, briefly washed, released from culture plates with trypsin-EDTA, and washed with icecold PBS containing Complete protease-inhibitor cocktail (Roche, Diagnostics, Indianapolis, IN). The cell pellet was homogenized in 250 mM sucrose, 3 mM imidazole, pH 7.4 (with 1 mM DTT and Complete), at 4°C by 10 passages through a 22 gauge needle. The homogenate was centrifuged at 300 g for 5 min to remove debris and nuclei. The resulting supernatant was diluted fivefold in extraction buffer (30 mM HEPES, 75 mM potassium acetate, 5 mM MgCl 2 , 100 μM ATP, 500 μM GDP) and incubated with 2 μM GDI fused to glutathione S-transferase (GST-GDI; a gift from William Balch, Scripps Research Institute) for 20 min at 30°C (18) . VP22-Rab9 bound to GST-GDI was recovered by binding to glutathione-Sepharose 4B beads (Amersham). Bound proteins were solubilized in SDS-PAGE sample buffer and analyzed by SDS-PAGE and immunoblotting with anti-Rab9 antibody. For an in vitro control, purified VP22-Rab9 fusion protein was added to homogenization buffer, diluted in extraction buffer, and subsequently processed as above.
Lipid analysis and microscopy of fibroblasts
For quantifying sterols, fibroblasts grown in culture dishes were washed, scraped, and homogenized in phosphate-buffered saline (PBS). Lipid extraction of homogenates and analysis on TLC were performed as described previously (19) . In some cases, the culture medium was collected, lyophilized, resuspended in PBS, and then processed for lipid extraction and analysis as above. Filipin-cholesterol staining (20) , Nile red staining (21) , and BODIPY-LacCer intracellular trafficking (4) were performed as described. Fluorescence images were obtained with an AX-70 microscope (Olympus America, Melville, NY) equipped with UPlanApo ×40 (1.00 N.A.) objective, and a CCD camera (Orca 100; Hamamatsu, Japan). Images were analyzed using MetaMorph V4.6.9 (Universal Imaging, Media, PA; ref 22) . At least 30 fields of multiple cells on the same (or identically treated) coverslips were analyzed for each calculation.
Neuronal cultures and analysis
Embryonic day 15 littermates from NPC1 heterozygous mouse matings were genotyped (23) , and neocortical tissue from normal and mutant homozygotes was dissociated with 0.05% trypsin for 5 min. Cells resuspended in medium were plated on poly-D-lysine coated coverslips, and cultures were maintained with Neurobasal medium (Invitrogen), B27 and 3% dialyzed FBS. Studies were performed on cultures at least 25 days in vitro (DIV), when neuronal accumulation of cholesterol and GM 2 ganglioside (GM 2 ) was evident (24) . Cultures were dosed once (2-day study) or again 2 and 4 days later (6 day study) with VP22-Rab9 or carrier in neuronal medium with 1% FBS. Neuronal viability was tested using the Live/Dead Eukolight kit from Molecular Probes.
Cultures were fixed with 4% paraformaldehyde and 0.1% picric acid, immunostained using antibodies to the neuronal somatodendritic marker microtubule-associated proteins 2 a and b (MAP2; Sigma, clone AP-20, mouse IgG) and to GM 2 (Progenics; clone 10-11, mouse IgM) followed by fluorescent secondary antibodies (ICN-Cappel), and then stained with filipin (23) . Specificity controls included substitution of primary antibodies with nonimmune mouse IgG or IgM (Sigma), or omission of filipin. Twelve-bit digital images were acquired on a Fluoview 500 confocal laser scanning system with a BX61WI microscope, a ×40 UAPO/340 water objective (NA 1.15) and ×2 scanner zoom, using ultraviolet argon (341-346 nm), 488 nm argon, and green HeNe (543 nm) lasers (Olympus). Appropriate settings were determined to avoid zero and saturated pixel values. For each condition, images of ~50 neurons from duplicate coverslips were collected double blind. For each field, an XY optical plane was chosen by focusing on MAP2 fluorescence, and then filipin, GM 2 , and MAP2 channel images were sequentially collected. No evidence of cross-channel talk or cross-reactivity was present. For analysis, the perimeter of neuronal cell bodies was defined using the Metamorph auto-trace function on MAP2 images. Total fluorescence intensity within this region of individual neurons was then measured for GM 2 or filipin staining after correction for background fluorescence. These "total intensity per neuron" data were used to calculate the mean and standard error for each experimental condition.
RESULTS

Expression, purification of VP22-Rab fusion proteins, and transduction of cells
We prepared a recombinant Rab9 protein with a VP22/NES/myc/polyHis fusion tag at the N terminus (designated VP22-Rab9; Fig. 1A ). The resulting construct was expressed in bacteria and purified by nickel chelate affinity column chromatography followed by gel filtration chromatography. Coomassie blue staining of SDS-PAGE gels showed that the eluate from the nickel column consisted of a ~47 kDa polypeptide and two ~22 kDa bands (Fig. 1B) . Western blots using antibodies against the myc epitope and Rab9 demonstrated that the 47 kDa protein was the full-length VP22-Rab9, whereas the major protein contaminants of ~22 kDa in the nickel column eluate were Rab9 fragments (data not shown). The full-length VP22-Rab9 band could be separated from the lower bands by gel filtration chromatography (Fig. 1B) .
Internalization of VP22-Rab9 into cells was assessed by Western blotting. NPC1 mut cells incubated for 48 h with the nickel column eluate containing 2.5 μM of VP22-Rab9 protein in EMEM with 1% FBS were scraped and homogenized. The internalized VP22-Rab9 protein present in the cell lysate was detected by immunoblotting using an anti-Rab9 antibody (Fig. 1C ). An immunoreactive band corresponding to full-length VP22-Rab9 was observed in treated cells, demonstrating internalization of the VP22-fusion protein. However, a ~22 kDa Rab9 fragment was also detected.
To determine if internalized VP22-Rab9 became prenylated, homogenates from NPC1 mut cells treated with VP22-Rab9 as above were incubated with GST-GDI followed by glutathioneSepharose beads. The bound proteins were subjected to SDS-PAGE and Western blotting for
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Rab9 as above. A significant signal for cell-associated VP22-Rab9 was detected bound to GST-GDI complexed to glutathione beads (Fig. 1D) , although this was only a small fraction of total VP22-Rab9 present in the homogenate fraction. When homogenates from NPC cells transduced with VP22-Rab9 were incubated with glutathione beads alone (without GST-GDI present), or when VP22-Rab9 was added to buffers alone in vitro and then incubated with GST-GDI, no binding of VP22-Rab9 to beads was detected (Fig. 1D) . Since Rab GDI is reported to bind only to prenylated GDP-bound Rabs (16, 17) , these results suggest that a portion of VP22-Rab9 internalized by the NPC1 mut cells became properly prenylated.
Correction of the NPC phenotype in NPC1 mut fibroblasts treated with VP22-Rab9
When added to NPC1 mut cells, the full-length VP22-Rab9 (lane 3 from Fig. 1B ) exhibited activity in reducing cellular cholesterol as assessed by filipin staining (Fig. 1E, Fr. 3) . By contrast, the fraction containing the ~22 kDa fragments (Fig. 1B, lane 4) did not reduce filipin staining (Fig.  1E , Fr. 4). These data suggest that the full-length VP22-Rab9 was the only effective component in the nickel column eluate. The nickel column eluate was used for all further experiments; all concentrations reported are based on the amount of protein in the 47 kDa band.
Untreated NPC1
mut fibroblasts show intensely bright punctate filipin staining, indicative of cholesterol accumulation ( Fig. 2A) , while normal fibroblasts exhibit little filipin fluorescence (data not shown; see refs 9, 25) . When NPC1 mut cells were incubated with 2.5 μM VP22-Rab9 for 48 h and fixed and stained with filipin, the intensity of the staining was reduced dramatically (Fig. 2A) . By contrast, when NPC1 mut cells were treated with 2.5 μM of VP22 ( Fig. 2A) , VP22-Rab9S21N (dominant-negative), or VP22-Rab9Q66L (constitutively active; data not shown) under the same conditions, no significant reduction in filipin staining was observed.
The decrease in cellular free cholesterol was also demonstrated by lipid analysis. After 48 h of treatment, cells were collected and the cell-associated lipids were extracted and quantified (Fig.  2B) . The levels of free cholesterol in untreated normal and NPC1 mut skin fibroblasts were 33 ± 4.8 μg/mg of protein and 48 ± 9.7 μg/mg of protein, respectively, similar to values reported by Frolov et al. (26) . Under the same assay conditions, NPC1 mut cells treated with VP22-Rab9 showed significant reduced free cholesterol levels (39±8.0 μg/mg protein) relative to untreated NPC1 mut fibroblasts (P<0.05), similar to the levels in untreated normal fibroblasts (Fig. 2B) . By contrast, treatment with VP22 alone did not affect cholesterol levels in NPC1 mut fibroblasts (Fig.  2B ). The differences in free cholesterol levels measured biochemically in NPC1 mut cells vs. VP22-Rab9-treated cells (Fig. 2B ) appear to be smaller than the differences in filipin staining between these cells ( Fig. 2A, C, and D) . However, our results are consistent with previous reports showing that moderate (e.g., 30-40%) increases in cellular free cholesterol result in dramatic intensification of filipin staining (19, 26, 27) .
The conditions for optimal VP22-Rab9 treatment were then examined. To study the dose dependency, NPC1 mut cells were incubated with 0-5 μM of VP22-Rab9 or VP22 for 48 h and stained with filipin, and the average intensity was quantified. A dose-dependent decrease in the intensity of filipin staining was observed with increasing concentrations of VP22-Rab9, reaching a plateau at 2.5 μM (Fig. 2C) . Trypan blue exclusion assays showed that VP22-Rab9 was not toxic to cells at concentrations up to 5 μM for periods of ≤48 h (data not shown).
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The time course of VP22-Rab9 treatment for reducing filipin staining was also investigated (Fig.  2D) . When NPC1 mut cells were incubated continuously with 2.5 μM VP22-Rab9 for various times and then stained with filipin, no significant changes were observed in the first 6 h. However, filipin intensity started decreasing slightly at 12 h and was reduced significantly at 24 and 48 h (Fig. 2D, continuous) . A similar trend was observed when the protein was eliminated from the culture medium after treatment for 6 h (Fig. 2D, pulse and chase) , suggesting that the internalized VP22-Rab9 was relatively stable.
We previously demonstrated that BODIPY-LacCer is targeted predominantly to the Golgi apparatus of normal HSFs, while in NPC1 mut (and other SLSD) fibroblasts, most of the lipid accumulates in punctate endosomal structures (Fig. 2E, untreated NPC) as a result of elevated cholesterol (4, 7). When NPC1 mut cells were treated with 2.5 μM VP22-Rab9, many of the cells now showed Golgi targeting of the LacCer analog, similar to that seen in normal HSFs (Fig. 2E) . The effect of VP22-Rab9 on LacCer targeting was dose-dependent, since a decrease in VP22-Rab9 concentration resulted in decrease in the extent of BODIPY-LacCer targeting to the Golgi (data not shown). These data confirm that treatment with VP22-Rab9 protein lowers intracellular cholesterol, thus correcting the BODIPY-LacCer targeting defects in NPC1 mut fibroblasts.
Fate of stored cholesterol after VP22-Rab9 treatment
Treatment of NPC1 mut fibroblasts with VP22-Rab9 for 48 h resulted in higher Nile red fluorescence than that in untreated NPC1 mut cells or NPC1 mut cells treated with VP22 only (data not shown), similar to our previous DNA transfection results (7) . In agreement with this cytochemical result, biochemical analysis showed a significant increase in cholesterol ester levels in NPC1 mut cells treated with VP22-Rab9 (Fig. 3A) . However, this increase in cellular cholesterol ester (~1 μg/mg protein) cannot account for the decrease in cellular free cholesterol (~10 μg/mg protein; see Fig. 2B ), suggesting other mechanisms contributed to reduction of cellular free cholesterol in NPC1 mut cells treated with VP22-Rab9.
We next examined the efflux of sterols into the culture medium on VP22-Rab9 treatment. The quantification of secreted sterols was difficult in 1% FBS because of the presence of serumderived sterols. Therefore, treatment with VP22-Rab9 was performed in medium containing LPDS. When the culture medium was collected after a 48 h treatment with VP22-Rab9, a significant increase in both free cholesterol and cholesterol ester levels was observed in the medium as compared with untreated NPC1 mut cells (Fig. 3B) . The increase in sterol effluxed into the medium in VP22-Rab9-treated NPC1 mut cells corresponded well with the extent of reduction of cell-associated free cholesterol.
These results suggested that VP22-Rab9 induced the transport of free cholesterol from late endosomes/lysosomes to the endoplasmic reticulum (ER) where cholesterol is esterified and also induced efflux of cellular sterols into the medium. Since transport of free cholesterol to the ER affects the protein levels or activities of many cholesterol-regulatory proteins and down-regulates the low density lipoprotein receptor (LDL R ), we compared the levels of LDL R in NPC1 mut cells treated with or without VP22-Rab9. As expected, VP22-Rab9-treated NPC1 mut cells expressed lower levels of the LDL R than untreated NPC1 mut cells (Fig. 3C) , supporting the idea that there is an increased transport of free cholesterol to the ER upon VP22-Rab9 treatment.
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Effect of VP22-Rab9 in other NPC subtypes and NPC neurons
The studies described above were performed on NPC1 mut fibroblasts with I1061T/P237S mutations in NPC1. To further characterize the potential of VP22-Rab9 for therapeutic use, we treated NPC1 null , NPC2 mut , and NPC2 null fibroblasts with VP22-Rab9 and assessed the intracellular cholesterol levels by filipin staining. When the cells were treated with the protein for 2 days in EMEM with 1% serum, none of these three additional NPC subtypes showed significant reduction in filipin staining unlike NPC1 mut fibroblasts (Fig. 4A) . Increasing incubation time from 2 to 7 days in the same culture medium did not improve the result (data not shown). However, when cells were treated for 7 days in EMEM with 5% FBS, all the VP22-Rab9 treated NPC subtypes showed significant reduction in filipin staining relative to untreated controls, although the decrease in filipin staining in NPC1 null and NPC2 null cells was not as dramatic as seen in NPC1 mut or NPC2 mut fibroblasts. These data suggest that this treatment may have potential benefit for both NPC1 and NPC2 genotypes. When 10% FBS in medium was used, however, none of the NPC subtypes including NPC1 showed reduction of filipin staining at 7 days (data not shown). We speculate that this high level of serum (10% FBS) interfered with the initial uptake of the VP22-Rab9 rather than its intracellular effects, since we previously demonstrated that transient transfection of Rab9 in NPC1 fibroblasts could dramatically lower filipin staining, even in the presence of 10% FBS (7).
To determine if treatment with VP22-Rab9 could also reduce intracellular free cholesterol in neurons, cultured mouse cortical NPC1 mut neurons were incubated with 5 μM VP22-Rab9 in media with 1% FBS for 2 or 6 days, fixed, and stained with filipin and antibodies against GM 2 ganglioside. In 25 DIV cultures incubated for 2 days, NPC1 mut neurons treated with VP22-Rab9 showed significantly lower levels (~50% reduction) of filipin staining than untreated NPC1 mut neurons (Fig. 4B) as well as some reduction in immunodetectable GM 2 ganglioside (data not shown). Allowing for greater progression of pathology, older cultures (38 DIV) were treated with VP22-Rab9 for 6 days. Here, a ~20% reduction in filipin fluorescence was observed for VP22-Rab9 treated relative to untreated NPC1 mut neurons (data not shown). No toxicity of VP22-Rab9 was observed during these treatments. These data demonstrate that treatment with VP22-Rab9 can reduce lipid storage in NPC1 mut neurons.
DISCUSSION
To study the role of Rab proteins in modulating lipid traffic and accumulation in NPC cells, and to further evaluate the potential therapeutic value of Rab9 expression in SLSDs, a VP22-Rab9 fusion protein was constructed, purified, and used for protein transduction. The present study demonstrated that treatment with the fusion protein could reduce accumulation of free cholesterol in NPC1 mut fibroblasts. Reduction in cellular free cholesterol in treated NPC1 mut fibroblasts was associated with correction of abnormal intracellular trafficking of BODIPYLacCer and the appearance of large amounts of sterols in the culture media. Clearance of lysosomal free cholesterol was also associated with a decrease in LDL R protein levels, confirming increased cholesterol delivery to the ER. Treatment with VP22-Rab9 protein also reduced free cholesterol accumulation in NPC1 null , NPC2 mut , and NPC2 null fibroblasts as well as NPC1 mut mouse neurons.
Page 8 of 17 (page number not for citation purposes)
The observations that Rab9 transfection (7, 10) or protein transduction (this study) reduces stored lipids in NPC fibroblasts suggest that endogenous Rab9 may not function properly in NPC cells. Our previous studies demonstrating that glycosphingolipid transport through the late endocytic compartment is defective in NP-C and other SLSD fibroblasts are consistent with this possibility (4, 8) . Recently, we found that the function of another endocytic Rab, Rab4, is perturbed in NP-C cells. This impairment in Rab4 was not due to a reduction in Rab4 expression but rather to inhibition of the membrane retrieval of Rab4 by GDI as a result of elevated endosomal cholesterol (18) . This inhibition of GDI/Rab4 interaction prevents the proper cycling of Rab4 between donor and target membranes. Similarly, inhibition of Rab7 extraction by GDI in cholesterol-overloaded cells has also been reported (28) . We propose that the interaction of certain Rab proteins (Rabs 4, 7, and 9) with GDI is selectively affected by elevated intracellular cholesterol, leading to accumulation of these Rabs on target membranes in an inactive state. Based on the current study, we suggest that delivery of exogenous wild-type Rab9, either by transduction (this study) or by transfection (7, 10) , supplies active Rab9 that is sufficient to restore critical membrane transport, thus allowing the eventual clearance of stored lipids (Figs. 2 and 3; refs 7, 18). Although we have also demonstrated a reduction of lipid storage in NPC cells by transfection of Rab7 (18) or Rab4 (unpublished results), we have not attempted to introduce these Rab proteins into cells by protein transduction.
While our previous study documented the reduction of intracellular free cholesterol on overexpression of Rab9 in NPC1 mut cells, the present study extended these results by demonstrating that Rab9 transduction could also reduce lipid storage in NPC1 null , NPC2 mut , and NPC2 null fibroblasts, as well as NPC1 null mouse neurons. In addition, the current study provides further insight into the mechanisms by which Rab9-mediated reduction of stored lipids occurs (7) . Namely, biochemical analyses demonstrated that treatment of NPC1 mut cells with VP22-Rab9 increased cell-associated cholesterol ester levels (Fig. 3A) and also stimulated the appearance of sterols in the culture medium (Fig. 3B) . This increase of sterols in the medium was sufficient to account for the loss of cholesterol from the VP22-Rab9 treated cells (Fig. 3B) . Cholesterol reduction was not dependent on the function of the NPC1 or NPC2 proteins, since cholesterol clearance also occurred in both NPC1-and NPC2-deficient cells (Fig. 4A) . Several different mechanisms for sterol efflux from cells have been described, including passive release of cholesterol from the plasma membrane to serum lipoproteins (29) , specific efflux by transporter proteins (e.g., ABCA1, CLA-1/SR-B1) to serum proteins, or active membrane shedding of "raft lipids" (30) . Our observation that the use of a higher concentration of serum (5% FBS) for a long-term treatment with VP22-Rab9 resulted in a higher degree of free cholesterol reduction in some NPC subtypes (Fig. 4A) suggests the involvement of serum protein carriers (e.g., ApoA1, HDL) for clearance of lysosomal free cholesterol. However, further studies will be required to establish the role of specific transporters and carrier proteins in this efflux process.
The mechanism by which Rab9 initiates a reduction in stored cholesterol in NPC endosomes is not fully understood. Here we showed that upon treatment with VP22-Rab9, total cholesterol ester recovered from NPC cells (including media) increased approximately twofold. This increased esterification suggests that VP22-Rab9 stimulates the transport of free cholesterol to the ER where it is esterified. Down-regulation of LDL R in NPC1 mut cells treated with VP22-Rab9 (Fig. 3C) confirms that there is increased cholesterol delivery to the ER. However, it should be noted that cholesterol ester formation might also take place in an endosomal compartment (31) or in the culture medium after cholesterol efflux.
Based on the known function of Rab9 in the transport of materials from late endosomes to the Golgi apparatus (7, 32) , and our finding that Rab9 expression (7) or VP22-Rab9 transduction (Fig. 2E ) are able to overcome the block in late endosome to Golgi apparatus transport of BODIPY-LacCer that exists in NPC cells, we suggest two potential mechanisms by which cholesterol might leave late endosomes following Rab9 transduction or expression. In the first model, Rab9 stimulates a vesicle-medated transport process in which cholesterol and SLs move together from late endosomes to the Golgi apparatus. This would be followed by retrograde transport of sterol from the Golgi to the ER. In the second model, Rab9 selectively stimulates the vesicular transport of SLs to the Golgi apparatus thereby reducing the interaction or "molecular trapping" of stored cholesterol with SLs in late endosomes (6, 19) . Cholesterol could then be transported by either a vesicular or nonvesicular mechanism to the ER or other sites, possibly bypassing the Golgi complex.
Translation of the observation that VP22-Rab9 can correct storage defects of cells in culture into a suitable therapeutic approach would require many levels of further study. The feasibility of Rab overexpression as a therapeutic treatment for NPC has yet to be tested in the NPC1 mut mouse model in vivo. VP22 and VP22 fusion proteins have been injected into mice with no reported toxicity (33, 34) , suggesting that VP22-Rab proteins could be introduced in animals in vivo for studies of lipid trafficking correction. Our findings showing efficacy in neurons are also encouraging in light of the involvement of these cells in NPC and the fact that treatment of the central nervous system storage diseases has been particularly problematic. An alternative approach of using appropriate viral vectors to express VP22-Rab proteins in vivo may be important to achieving neuronal correction (35, 36) . Our study suggests that the general principle of stimulating membrane transport may be worth considering as a therapeutic approach for the treatment of NPC, and potentially, other SLSDs (5, 6). Searches for new pharmaceuticals that stimulate vesicular transport (or repress inhibitors of transport) may yield new compounds which could be useful in SLSDs and other diseases. The 47 kDa VP22-Rab9 fusion protein consists of VP22 at the N terminus, nuclear export signal (NES), myc epitope, and poly-histidine sequences followed by Rab9. Dominant-negative and constitutively active Rab9 mutants, having a single mutation of S21N and Q66L, respectively, were also generated by site-directed mutagenesis. B) Overexpression and purification of VP22-Rab9 protein. Fusion protein was overexpressed in E. coli and purified on a nickel-chelate column followed by gel filtration chromatography. Lanes: M, molecular weight marker; 1, crude extract; 2, elute from His•Bind column; 3, fraction 3 from Superose 12 column containing highly enriched full-length VP22-Rab9 protein; 4, fraction 4 from Superose 12 column containing Rab9 fragments without VP22 tag. C) Protein transduction of VP22-Rab9 into NPC1 mut human skin fibroblasts. Purified VP22-Rab9 protein was added to culture medium to final concentration of 2.5 µM. After 48 h incubation with or without VP22-Rab9, cells were scraped, homogenized, and analyzed by Western blotting using anti-Rab9 monoclonal antibody; 10 µg of protein were loaded in each lane. D) Interaction of VP22-Rab9 with Rab GDI. Homogenates from VP22-Rab9-transduced NPC1 mut fibroblasts (cellassociated) or purified VP22-Rab9 (in vitro) were incubated ± GST-GDI and then with glutathione-Sepharose beads (see Materials and Methods). Samples were analyzed by SDS-PAGE and Western blotting using an anti-Rab9 antibody. Starting fractions (initial) for cell-associated or in vitro VP22-Rab9 were loaded on gels at 2 and 5%, respectively, of the amount incubated ± GST-GDI and glutathione-Sepharose beads; 100% of each bead pellet was run on gels. mut , NPC1 null , NPC2 mut , or NPC2 null were treated with (white bars) or without (black bars) 2.5 µM VP22-Rab9 as indicated. For 7-day treatment, medium ± VP22-Rab9 was replaced daily. After treatment, filipin staining was quantified. B) Reduction of free cholesterol in NPC1 mut mouse neurons. Neurons from NPC1 mut mice were treated at 25 DIV ± VP22-Rab9 for 2 days in 1% FBS, fixed, and stained with filipin, and intensity per cell body was quantified in a blinded study (see Materials and Methods). Difference between controls vs. VP22-Rab9 treated neurons was significant (Mann-Whitney test) for filipin (P<0.001). Values in A and B are percentage of those in untreated NPC1 mut controls and are means ± SE.
